“…….The study highlighted the under-utilisation of CKD monitoring tools in primary care environments.
Only 21 of the surveyed nations reported the use of routine serum creatinine with estimated glomerular filtration rate….”
]]>
Cork, Ireland – Oct 27th, 2016 – Radisens Diagnostics, a Cork based medical diagnostics company which specialises in developing near-patient devices that instantly test and monitor for high-burden chronic diseases, today announced a contract worth €1.6 million with the European Space Agency (ESA). The partnership is supported by the Department of Jobs, Enterprise and Innovation through Enterprise Ireland and is the third contract agreed between Radisens and ESA in recent years. .
The new contract will see the company integrate multiple technologies required for human spaceflight onto its novel Gemini™ platform, a multi-mode device which allows for decentralised diagnostics. The resulting device will be used aboard the International Space Station and on various human spaceflight missions in the future. The technologies to be developed under the ESA programme will also have potential applications for use on earth to monitor the health of patients diagnosed with chronic diseases such as diabetes and heart disease, by testing a fraction of a blood droplet through a single device.
Radisens’ CEO, Jerry O’Brien, expressed his delight with the deal saying that “we are very pleased to extend our long-term partnership with ESA, to develop real-time blood testing technologies for use in space. There are many parallels between blood testing requirements for both space and clinical use such as ease-of-use, compact devices, fast turnaround time and removing the use of needles. Our solutions for the tougher space requirements will benefit both patients and clinicians to better manage chronic disease as we integrate them into our commercial product.”
ESA’s Technical Officer, Francois Gaubert, welcomed this partnership extension saying “Moving forward in the development of such a technology with Radisens is a very exciting goal and experience. Blood analysis on astronauts has always been dependent on the return to earth of the samples. Hopefully in the near future, physiological parameters of Astronauts onboard the ISS could be monitored within minutes. This would be a major step towards the use of Point of Care diagnostics during future manned exploration missions e.g. a long duration mission to a lunar outpost. The needs of potential space applications will be served by the miniaturization, robustness, and the easy-to-use qualities of the commercial device.”
In congratulating the company, Minister of State for Training, Skills and Innovation, Mr. John Halligan TD said “I wish to congratulate Radisens Diagnostics on winning another valuable contract with the European Space Agency. It clearly demonstrates the capacity of Irish companies to develop highly innovative technologies to meet the highly demanding requirements for space. Radisens Diagnostics is one of a growing number of Irish companies benefitting from the Irish Governments investment in ESA to build new products, new markets and support high value job creation in Ireland.”
Tony McDonald, Programme Manager Enterprise Ireland added “Radisens is one of a growing number of companies developing highly innovative technologies for the commercial market with support from the European Space Agency. We expect to see the number of Irish companies engaging with ESA to grow steadily over the next three years.”
Notes to the Editor:
About Radisens Diagnostics
Radisens’ mission is to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland
The European Space Agency
The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. ESA develops the launchers, spacecraft and ground facilities needed to keep Europe at the forefront of global space activities. Today it launches satellites for Earth observation, navigation, telecommunications and astronomy, sends probes to the far reaches of the Solar System and cooperates in the human exploration of space. www.esa.int
ESA plays a critical role in developing a strong European Space programme and space industry and has been fundamental to in developing the specialised, highly innovative, industrial capabilities that exist in the Irish space sector. ESA :-
More details on Enterprise Ireland, managing Ireland’s investment in the European Space Agency
Enterprise Ireland co-ordinates Ireland’s industrial and research participation in the programmes of the European Space Agency (ESA) in collaboration with the Department of Jobs, Enterprise and Innovation.
The purpose of Ireland’s membership of ESA is to participate in European space programmes with a focus on facilitating innovative Irish companies to develop leading edge space technologies and to commercially exploit their ESA participation in global space and non-space markets, leading to increased export sales and employment.
Enterprise Ireland’s role in relation to ESA is to assist Irish companies to successfully bid for ESA contracts, providing expertise for Irish companies and researchers in developing and executing space strategies, as well as being a point of reference for the international space industry when they want to identify relevant sources of space-related expertise within Ireland.
Irish industrial and research participation in ESA covers a range of sectors and technology areas including; software, precision mechanical engineering, telecommunications, electronics, optoelectronics and advanced materials and extending to end user equipment, services and applications.
]]>Red Herring Top 100 Europe enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the European Region. Since 1996, Red Herring has kept tabs on these up-and-comers. Red Herring’s Top 100 list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring’s editors were among the first to recognize that companies such as Alibaba, Facebook, Google, Kakao, Skype, SuperCell, Spotify, Twitter, and YouTube would change the way we live and work. Thousands of the companies most interesting and innovative companies have graced the Top 100 list over the years.
Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technological innovation, management quality, overall business strategy and market penetration. This assessment was complemented by a review of the track records and standings of similar startups in the same verticals, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Europe.
The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across Europe. The nominees were evaluated on 20 main quantitative and qualitative criterion: they include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland.
]]>Cork – Jun 23, 2015 – Radisens Diagnostics, a medical diagnostics company developing a near-patient device to instantly test for high-burden chronic disease anywhere, announced today that it has been awarded a €4.5m grant from the European Commission’s SME Instrument initiative. As part of the EC’s Horizon 2020 Research and Innovation programme, the €3bn SME Instrument hand-picks potentially disruptive businesses to invest and support.
“We are delighted with this significant endorsement from the EC, in support of our vision of instant testing of any high-burden chronic disease anywhere”, commented Radisens’ CEO, Jerry O’Brien. “Integrating diabetes, cardiovascular and kidney function panels onto Gemini™ will impact people’s daily lives”. Radisens will use the funds to integrate such panels on to its Gemini™ near-patient platform, giving instant results from a fraction of a drop of blood.
Near-patient blood testing is one of the fastest growing segments of the healthcare industry, fuelled by the push towards improving patient outcomes, healthcare efficiencies and quality standards. It closes the linkage between diagnostics and therapeutics, as current lab tests require days before results are available. O’Brien adds, “Radisens’ vision is that of a confirmed diagnosis, clinical counselling and prescribed therapies all within a single physician or pharmacy visit, without fear of needles or anxious days of waiting for results, thereby empowering patients to better manage their chronic disease”.
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland
About the EC’s Horizon 2020 & SME Instrument
Horizon 2020 is the biggest European Commission Research and Innovation programme ever with nearly €80bn of funding available over 7 years (2014 to 2020). Horizon 2020 funds high-potential innovation through a dedicated SME instrument. Provided with about €3bn in funding over the period, the SME Instrument helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition. Available to SMEs only, the new scheme has opened a new highway to innovation through phased, progressive and complimentary support.
The dedicated SME instrument’s supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. More details are available at the Horizon 2020 SME Instrument portal.
Commercial Contact:
Jerry O’Brien, Radisens Diagnostics Ltd.
E: info (at) radisens.org
T: +353 21 233 9140
Additionally, Radisens has been selected to present at the OneMedForum conference, which runs concurrently with the J.P. Morgan conference. OneMedForum is an industry summit focusing on partnering with, and investment in, select high growth healthcare SME’s.
“We are honored to be chosen as one of the high growth potential companies presenting”, said Jerry O’Brien, CEO. “The conference provides an excellent venue for Radisens to showcase our vision of instant blood testing for all at the point of care, our progress so far and how this pioneering work will improve patient outcomes and reshape blood diagnostics forever”.
]]>Make, Create, Innovate is dedicated to science and technology, telling stories behind the inventions and technological breakthroughs that are reshaping the world. Radisens’ CEO will offer insights on his vision of instant blood testing for all, the journey so far and how this pioneering work will reshape blood testing forever.
The show broadcasts into more than 280 million homes around the world and streams online at CNN.com, which receives more than 10 million views daily.
]]>The European Space Agency has contracted Radisens to extend the blood testing menu on their point-of-care device which is currently in development at their facility at the Rubicon Centre, Cork. This forerunner device could be used on board the International Space Station and on various human spaceflight missions where it is essential to get high-performance, laboratory grade results for myriad health conditions, without fear of biological contamination.
Radisens’ CEO, Jerry O’Brien, commented “We are delighted to extend our successful partnership with ESA. The operational needs on board the International Space Station, which requires leading-edge performance, ease-of-use and biological containment, provide Radisens with a unique test-bed for our game-changing point-of-care platform”.
Congratulating the company, Sean Sherlock, TD, Minister for Research and Innovation and the Minister with policy responsibility for space matters said “Radisens is another excellent example of how innovative Irish companies are leveraging the Irish Government’s investment in the European Space Agency. Space is proving to be a very fertile ground for Irish companies in developing innovative technologies and proving the technologies performance in extreme environments. The Radisens example also clearly shows how technologies developed for space can have a major societal impact here on Earth in improving human healthcare. We want to see indigenous companies like Radisens scale up and grow to create jobs here in Ireland, and winning internationally benchmarked contracts like this will help them achieve this”.
ESA’s Technical Officer, Francois Gaubert, added “Performing rapid analysis of astronauts’ blood samples and monitoring their physiological parameters onboard the ISS without having to download the samples from the ISS to the ground laboratories is a feature with utmost interest that the RADISENS POC proposes to develop”.
Tony McDonald, Enterprise Ireland pointed to Radisens as one of a growing number of Irish companies which are looking to ESA to support their product and market development strategies. The partnership with ESA is proving to be highly beneficial to Irish companies in supporting technology development, product reliability and performance and in providing a globally recognised reference customer.
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland.
About Enterprise Ireland and the European Space Agency
The European Space Agency (ESA) is the intergovernmental organisation that promotes co-operation among European States in space research and technology and their space applications for scientific purposes and for operational space applications systems. Ireland’s membership of ESA permits Irish companies and research teams to bid for ESA contract development work in a range of space programmes.
Enterprise Ireland is the Irish body responsible for co-ordinating Ireland’s industrial and research participation in the programmes of ESA. Its role is to assist Irish companies to successfully bid for ESA contracts. Enterprise Ireland provides a source of expertise for Irish companies in developing and executing space strategies, Irish industrial participation is primarily in the engineering, aerospace, software, electronics, optoelectronics and telecommunications sectors.
The level of spin off export sales (including direct ESA contracts) from Irish investment in ESA is estimated at €50m in 2013 and projected to grow substantially as the number of Irish companies securing ESA contract continues to expand, and as existing Irish ESA contractors progress from intensive R&D phase to commercial exploitation phase.
Commercial contacts:
Jerry O’Brien
Radisens Diagnostics Ltd.
E: info (at) radisens.org
T: +353 21 4868195
“Radisens’ miniaturised POC device and consumable platform integrates different combinations of multiplexed high-sensitivity immunoassays, clinical chemistries, and haematology (cell counting) assays onto single consumable panels,” explained Frost & Sullivan Healthcare Industry Analyst Prasanna Vadhana Kannan. “These panels initially target long-term chronic disease management of thyroid disorders, chronic diabetes, cardiovascular disease, chronic kidney disease, and cell counting.”
This single device thereby effectively replaces the ten to fifteen stand-alone instruments that a physician would typically require for routine blood testing. Moreover, the interpretation of lab-grade data is instantaneous. All sample preparation and blood testing procedures are integrated into the test panel, thereby enabling accurate, highly sensitive, repeatable, sample-to-answer and quality assured results.
“Radisens’ technology platform is truly considered disruptive,” added Kannan. “It seamlessly converges consumer electronics, centrifugal microfluidics, and assay development to achieve smart decentralisation of medical diagnostics from a central reference laboratory into POC settings.”
This platform requires only a finger prick of blood and can deliver clinical results within minutes of blood draw. Through this approach, patients are more likely to improve prescription compliance and, in turn, significantly contribute toward a reduction in the risk factors for chronic disorders. This will impart healthcare systems globally with a much needed tool to combat rising chronic disease management costs.
Notable features that distinguish Radisens’ solution from other competing POC devices in the market include: all assay and sample preparation steps integrated onto a consumable panel, central reference laboratory performance, solid-state digital detection, analyte microanalysis algorithms, and, a single integrated device platform capable of multiplexed diagnostics across the three primary blood test categories of immunoassays, clinical chemistries and cell counting.
“Overall, the potential for Radisens’ diagnostic platform based on its real-time connectivity, sample-to-answer operation, high-degree of multiplexing, and low cost features is immense and is poised to revolutionise the integrated POC diagnostics market,” concluded Kannan.
Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of the uniqueness of its technology and its potential impact on new products/applications, on functionality and on customer value. The company is also commended for the relevance of this innovation to industry.
Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Commercial contacts:
Jerry O’Brien
Radisens Diagnostics Ltd
E: info (at) radisens.org
T: +353 21 4868190 / Fax: +353 21 4928909
Emily Bailey
Best Practices, Frost & Sullivan
E: [email protected]
T: +44 (0)20 7915 7869
As part of the HIH, Radisens is planning a clinical reference testing site in partnership with the HSE and local hospitals. Access to the local healthcare system will allow the company to test and validate their advanced point-of-care technology in a controlled and regulated environment ahead of commercial launch. With Ireland spending up to €1.45 billion annually on managing chronic diabetes alone, the clinical reference site will pilot the design and efficient integration of this disruptive technology, which promises huge savings for chronic disease management.
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland.
Commercial contact:
Jerry O’Brien
Radisens Diagnostics Ltd.
E: info (at) radisens.org
T: +353 21 4868190 / Fax: +353 21 4928909
Comprising part of Radisens point-of-care diagnostic platform, the proprietary digital HDR™ detection engine delivers industry leading multi-colour fluorescence and scattering sensitivity. This matchbox-sized HDR™ detection engine delivers a step-change in the market for portable multi-fluorescent flow cytometers, cell analysers and diagnostic devices. The six decades of optical dynamic range enables truly automatic sample-to-answer operation, with the digital solid-state technology removing the need for expensive maintenance cycles, while significantly reducing instrument cost.
Jerry O’Brien, CEO of Radisens Diagnostics said, “This strategic collaboration with Beckman Coulter demonstrates the disruptive nature of the diagnostics technology that we are developing at Radisens in terms of performance, cost and usability. This opens up huge growth opportunities in providing clinicians and researchers a powerful, low-cost diagnostic tool onto their desk with the advanced laboratory performance they require.”
Commenting on the deal, Mario Koksch, Director Product Management for Flow Cytometry at Beckman Coulter, Inc., said “We are very excited by the potential performance, cost and usability benefits that Radisens can bring with its proprietary HDR™ detection technology. We look forward to realizing the huge potential this offers within emerging high-growth flow cytometry markets, while maintaining a reputation for high performance.”
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland.
About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, CA, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 275,000 Beckman Coulter systems operate in both diagnostics and life sciences laboratories on six continents. For more than 75 years, Beckman Coulter products have been making a difference in peoples’ lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and reducing the cost of care. For more information, visit www.beckmancoulter.com.
Commercial contact:
Jerry O’Brien
Radisens Diagnostics Ltd.
E: info (at) radisens.org
T: +353 21 4868190 / Fax: +353 21 4928909